Press Releases

Press Releases

DateTitle 
May 29, 2020
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders Data Includes Additional Patients with Advanced Refractory Renal Cell Cancer, Supporting Earlier Results
May 27, 2020
BURLINGAME, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient
May 13, 2020
BURLINGAME, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient
Apr 30, 2020
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the
Apr 22, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Mar 05, 2020
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the
Feb 28, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Feb 19, 2020
BURLINGAME, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Richard A. Miller , M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted
Feb 13, 2020
BURLINGAME, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated
Feb 01, 2020
BURLINGAME, Calif. , Feb. 01, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated